Immunomodulatory effect of bisphosphonate risedronate sodium on CD163 + arginase 1+ M2 macrophages: The development of a possible supportive therapy for angiosarcoma

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Fujimura, Taku ^a   Kambayashi, Yumi ^a   Furudate, Sadanori ^a   Kakizaki, Aya ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD163 ANTIGEN; CXCL11 CHEMOKINE; DOCETAXEL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INTERLEUKIN 10; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; RANTES; RISEDRONIC ACID; THYMUS AND ACTIVATION REGULATED CHEMOKINE; ARGINASE; CALCIUM CHANNEL BLOCKING AGENT; CELL SURFACE RECEPTOR; CYTOKINE; DIFFERENTIATION ANTIGEN; DRUG DERIVATIVE; ETIDRONIC ACID; IMMUNOLOGIC FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUKOCYTE ANTIGEN; TAXOID;

ANGIOSARCOMA; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; MACROPHAGE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; BIOLOGICAL MODEL; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; TH2 CELL;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARGINASE; CALCIUM CHANNEL BLOCKERS; CYTOKINES; ETIDRONIC ACID; HEMANGIOSARCOMA; HUMANS; IMMUNOLOGIC FACTORS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MODELS, BIOLOGICAL; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TAXOIDS; TH2 CELLS;

EID: 84893181738     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/325412     Document Type: Article

References (18)

1. Sasaki R., Soejima T., Kishi K., Imajo Y., Hirota S., Kamikonya N., Murakami M., Kawabe T., Ejima Y., Matsumoto A., Sugimura K., Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome. International Journal of Radiation Oncology, Biology, Physics 2002 52 4 1032 1040 2-s2.0-18344388640 10.1016/S0360-3016(01)02753-5 (Pubitemid 34219024)
2. Ward J. R., Feigenberg S. J., Mendenhall N. P., Marcus R. B. Jr., Mendenhall W. M., Radiation therapy for angiosarcoma. Head and Neck 2003 25 10 873 878 2-s2.0-0141704426 10.1002/hed.10276 (Pubitemid 37139900)
3. Koontz B. F., Miles E. F., Rubio M. A. D., Madden J. F., Fisher S. R., Scher R. L., Brizel D. M., Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head and Neck 2008 30 2 262 266 2-s2.0-39149092712 10.1002/hed.20674 (Pubitemid 351251711)
4. Ishibashi M., Fujimura T., Hashimoto A., Haga T., Onami K., Tsukada A., Kambayashi Y., Hidaka T., Furudate S., Shimada R., Aiba S., Successful treatment of MMP9-expressing angiosarcoma with low-dose docetaxel and biphosphonate. Case Reports in Dermatology 2012 4 5 9
5. Kambayashi Y., Fujimura T., Furudate S., Hashimoto A., Haga T., Aiba S., Comparison of immunosuppressive cells and cytotoxic cells in angiosarcoma: the development of a possible supportive therapy for angiosarcoma. Dermatology 2013 227 14 20
6. Kambayashi Y., Fujimura T., Aiba S., Comparison of immunosuppressive cells and immunomodulatory cells in kerartoacanthoma and invasive squamous cell carcinoma. Acta Dermato-Venereologica 2013 93 6 663 668 10.2340/00015555-1597
7. Groom J. R., Luster A. D., CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunology and Cell Biology 2011 89 2 207 215 2-s2.0-79951944636 10.1038/icb.2010.158
8. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., Liu B., Deng H., Wang F., Lin L., Yao H., Su F., Anderson K. S., Liu Q., Ewen M. E., Yao X., Song E., CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011 19 4 541 555 2-s2.0-79953747613 10.1016/j.ccr.2011.02. 006
9. Plönes T., Krohn A., Burger M., Veelken H., Passlick B., Müller-Quernheim J., Zissel G., Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. PLoS ONE 2012 7 e41746
10. Miyagaki T., Sugaya M., Suga H., Ohmatsu H., Fujita H., Asano Y., Tada Y., Kadono T., Sato S., Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis. Journal of the European Academy of Dermatology and Venereology 2013 27 1 e60 e67 2-s2.0-84857927577 10.1111/j.1468-3083.2012.04495.x
11. Nagano T., Yamada Y., Ikeda T., Kanki H., Kamo T., Nishigori C., Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 2007 110 3 648 651 2-s2.0-34547130553 10.1002/cncr.22822 (Pubitemid 47106155)
12. Heymann D., Ory B., Gouin F., Green J. R., Rédini F., Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends in Molecular Medicine 2004 10 7 337 343 2-s2.0-3042796964 10.1016/j.molmed. 2004.05.007 (Pubitemid 38881523)
13. Fujimura T., Furudate S., Kambayashi Y., Aiba S., Potential use of bisphosphonates in invasive extramammary Paget's disease: an immunohistochemical investigation. Clinical and Developmental Immunology 2013 2013 6 10.1155/2013/164982 164982
14. Jagdev S. P., Coleman R. E., Shipman C. M., Rostami-H A., Croucher P. I., The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. British Journal of Cancer 2001 84 8 1126 1134 2-s2.0-0035917560 10.1054/bjoc.2001.1727 (Pubitemid 32448513)
15. Fehm T., Zwirner M., Wallwiener D., Seeger H., Neubauer H., Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer 2012 12, article 308
16. Melani C., Sangaletti S., Barazzetta F. M., Werb Z., Colombo M. P., Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research 2007 67 23 11438 11446 2-s2.0-37049006066 10.1158/0008-5472.CAN-07-1882 (Pubitemid 350248572)
17. Kodumudi K. N., Woan K., Gilvary D. L., Sahakian E., Wei S., Djeu J. Y., A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clinical Cancer Research 2010 16 18 4583 4594 2-s2.0-77956680680 10.1158/1078-0432.CCR-10-0733
18. Vogel C., Marcotte E. M., Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nature Reviews Genetics 2012 13 4 227 232 2-s2.0-84858439862 10.1038/nrg3185